{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-033362","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.016443+00:00","generated_at":"2026-05-17T00:27:33.395297+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vaxart signs exclusive license with Dynavax for oral COVID-19 vaccine; $25M upfront, $5M equity investment","bullets":["Dynavax pays $25M upfront license fee and $5M equity (11.1M shares at $0.45/share) for worldwide rights to Vaxart's oral COVID-19 vaccine.","Vaxart retains responsibility to complete ongoing Phase 2b trial (enrolled ~5,400; topline data expected late 2026) and EOP2 meeting.","After Phase 2b data, Dynavax can elect to assume development for $50M additional payment; otherwise agreement terminates.","If Dynavax continues, Vaxart eligible for up to $195M regulatory milestones, $425M sales milestones, and low-to-mid teens royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-033362","json":"https://secwatch.observer/filing/0001437749-25-033362.json","markdown":"https://secwatch.observer/filing/0001437749-25-033362.md","text":"https://secwatch.observer/filing/0001437749-25-033362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774925033362/0001437749-25-033362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774925033362/vxrt20251104_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:27:33.395297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}